Moody's Investors Service, a division of the Moody's Corporation, downgraded the ratings outlook for InVentiv from stable to negative.
The CRO side of the drug development business has been consolidating at a rapid pace over the last 12 months. And inVentiv Health is helping accelerate that trend with the news that it is snapping up
Just weeks after putting itself up for sale, CRO PharmaNet has agreed to merge with affiliates of private equity group JLL Partners. JLL will pay $5 a share for all outstanding shares of PharmaNet,
Princeton, NJ-based CRO PharmaNet Development Group said it's talking with a financial advisor to pursue "strategic alternatives," including the possible sale of the company. PharmaNet makes the